Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
Healthcare
$1.52 +2.22%
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
52W Low $1.28High $9.50
Volume 0.12M
Average 0.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$15.62M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$7.28M
FY 2025 · Annual
-56.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.26M) |
| Depreciation & Amortization | 0 | 0 | 0 | 12.18K | 2.06K |
| Deferred Income Tax | 0 | 0 | 0 | (503) | 221.1K |
| Stock-Based Compensation | 322.88K | 582.66K | 619.97K | 476.02K | 355.64K |
| Change in Working Capital | (52.19K) | 197.38K | (194.45K) | (581.27K) | (133K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 270.01K | 219.3K | (461.25K) | 219.89K | (532.61K) |
| Other Working Capital | (322.2K) | (21.92K) | 266.81K | (801.16K) | 399.6K |
| Other Non-Cash Items | 0 | 0 | 0 | 3.65M | 18.19M |
| Operating Cash Flow | (15.69M) | (11.47M) | (4.87M) | (8.79M) | (15.62M) |
| Capital Expenditures | 0 | (3) | 0 | 5 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 3.76M | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 3.76M | 0 |
| Debt Repayment | 0 | 0 | 0 | 15.32M | 3M |
| Common Stock Issued | 0 | 4.49M | 1.16M | 1.38M | 4.34M |
| Common Stock Repurchased | (295.17K) | 0 | 0 | (351) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 197.56K | 0 | 0 | 0 | (53.81K) |
| Financing Cash Flow | (97.6K) | 4.49M | 1.16M | 16.7M | 7.28M |
| Effect of Forex Changes | 0 | 0 | 0 | (144.59K) | 10.64K |
| Net Change in Cash | (15.79M) | (6.98M) | (3.71M) | 11.53M | (8.32M) |
| Free Cash Flow | (15.69M) | (11.47M) | (4.87M) | (8.79M) | (15.62M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$34.3M
+ D&A$2.1K
+ Stock-Based Comp$355.6K
+ Deferred Tax$221.1K
- Working Capital-$133.0K
+ Other Non-Cash$18.2M
= Operating Cash Flow-$15.6M
- Capex$0
= Free Cash Flow-$15.6M
Analysis
FY2025 free cash flow is -$15.6M. FCF conversion is 45.6% of net income. Operating cash flow was -$15.6M, with capex of $0. The largest bridge item is Other Non-Cash at $18.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 7, 2025 | |
| 8-K | Current report | Nov 6, 2025 | |
| DEF 14A | DEF 14A filing | Oct 20, 2025 | |
| S-3/A | S-3/A filing | Oct 16, 2025 | |
| DEFA14A | DEFA14A filing | Oct 9, 2025 |
Does DWTX generate free cash flow?
Dogwood Therapeutics, Inc. (DWTX) generated -$15.62M of free cash flow in fiscal 2025.
How much operating cash flow does DWTX produce?
Operating cash flow was -$15.62M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.